CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 216 enrolled
Drug / intervention
Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)drug
Likely dose
Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00997139
NCT00997139N/ACompleted

Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment

Northwestern University·interventional·Posted Oct 19, 2009·Updated Jan 5, 2015

In Brief

A clinical study evaluating Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg) for Nasal Carriers of Staphylococcus Aureus. Completed, enrolled 216 participants across 1 site.

Detailed Summary

Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 19, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.7 years ago

Interventions

Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)drug

2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.